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Abstract
Cancer is associated with increased fracture risk, due either to metastasis or associated osteoporosis. After a fracture, blood
clots form. Because proteins of the coagulation cascade and activated platelets promote cancer development, a fracture in
patients with cancer often raises the question whether it is a pathologic fracture or whether the fracture itself might
promote the formation of metastatic lesions. We therefore examined whether blood clot formation results in increased
metastasis in a murine model of experimental breast cancer metastasis. For this purpose, a clot was surgically induced in the
bone marrow of the left tibia of immundeficient mice. Either one minute prior to or five minutes after clot induction, human
cancer cells were introduced in the circulation by intracardiac injection. The number of cancer cells that homed to the
intervention site was determined by quantitative real-time PCR and flow cytometry. Metastasis formation and longitudinal
growth were evaluated by bioluminescence imaging. The number of cancer cells that homed to the intervention site after
24 hours was similar to the number of cells in the opposite tibia that did not undergo clot induction. This effect was
confirmed using two more cancer cell lines. Furthermore, no difference in the number of macroscopic lesions or their
growth could be detected. In the control group 72% developed a lesion in the left tibia. In the experimental groups with
clot formation 79% and 65% developed lesions in the left tibia (p = ns when comparing each experimental group with the
controls). Survival was similar too. In summary, the growth factors accumulating in a clot/hematoma are neither enough to
promote cancer cell homing nor support growth in an experimental model of breast cancer bone metastasis. This suggests
that blood clot formation, as occurs in traumatic fractures, surgical interventions, and bruises, does not increase the risk of
metastasis formation.
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Introduction
Breast and prostate cancer represent the most common solid
tumors in adults associated with bone metastasis [1]. These
metastases originate from circulating cancer cells that hijack the
hematopoietic stem cell niches in the bone marrow taking
advantage of its unique richness in cytokines [2–4]. The growth
of a metastatic lesion in the bone often increases the risk of a
pathologic fracture [5,6]. These fractures are mostly predictable
[7] and largely contribute to a worsened quality of life in patients
with metastatic bone disease [5]. While most fractures occur in the
presence of a metastatic lesion, cancer is often associated with
osteoporosis and hence an increase in fracture risk [8]. Occasion-
ally, a fracture site is later found to contain metastatic disease.
Therefore the question occasionally arises as to whether the
occurrence of a fracture in a patient with cancer is a reflection of
the presence of a metastatic lesion at the fracture site or whether
the pathologic processes that take place in the event of a fracture
increase the risk of establishment of tumor cells at the site of the
fracture.
One of the first events that take place after a fracture is the
development of a hematoma, in which the coagulation cascade is
activated. Blood clots include a number of proteins that have been
shown to directly affect tumor development. Thrombin, a terminal
clotting protein, supports cancer implantation and growth [9].
Factor XIII stabilizes thrombi and supports metastasis formation
by interfering with natural-killer mediated cancer cell removal
[10]. Fibrinogen, another molecule involved in the clotting
cascade was shown to support cancer cell adhesion and survival
[11]. Other participants in the coagulation cascade such as tissue
factor have been associated with metastatic disease in correlative
studies and a causative role is presumed albeit not proven [12,13].
Furthermore, the platelets themselves produce SDF-1 (stromal-cell
derived factor-1), which can act as a chemotactic agent for cancer
cells [14]. Thus, molecules upregulated in the early stages of clot
formation or in fracture hematomas and proteins concentrated
there as a result of coagulation activation that support infiltration
by inflammatory cells can also be involved in tumor development.
Indeed, interfering with some of these events seems to negatively
affect cancer development [15,16].
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Based on these and other studies one might be inclined to
conclude that the formation of a blood clot as might occur in
fractures is associated with the development of metastatic disease.
We therefore aimed to test whether the development of a blood
clot can be directly responsible for the formation of a metastatic
lesion. This seems particularly relevant in view of observational
studies suggesting that events associated with tooth extraction are
enough to increase the rate of metastasis formation [17]. To
achieve this aim, we used an experimental model, in which a blood
clot is induced in the left tibia. Cancer cells selected to home to the
bone marrow were then introduced in the circulation by means of
intracardiac injection to ensure the presence of large numbers of
circulating cancer cells at the time of clot formation [18]. Using
this model we examined the homing of cancer cells to the blood
clot in the bone marrow in the left tibia in comparison to the
opposite side that did not undergo clot induction. We also
compared the development of metastatic lesions in these mice to
control mice that did not undergo clot induction. We found
neither an increase in the number of cancer cells localized to the
clot nor an increase in the number of metastatic lesions developing
in the injured left tibia. This suggests that the formation of clots/
hematomas, albeit rich in growth factors does not provide optimal
conditions for cancer growth. Thus there is currently no evidence
to support fear of increased metastasis formation after clot
formation as might occur in fractures and surgical interventions.
Methods
Mice
CD1 nu/nu animals were obtained from Charles River
Laboratories (Kissleg, Germany). These mice carry a foxn mutation
that results in their inability to produce functional T cells and
therefore these animals are suited for a xenotransplant model. In
addition, hair follicle development is impaired, and hence these
mice are nude, allowing for bioluminescence imaging without
shaving.
The studies in mice were approved by the animal protection
committee of the University of Heidelberg and Regierungspra¨si-
dium Karlsruhe #G48/08, #G120/11, #G73/13 and #G136/
13, thus, all animal work was conducted according to relevant
national and international guidelines. All surgery was performed
under anesthesia, and all efforts were made to minimize suffering.
Cancer cells
MDA-MB-231B/luc+ or PC-3M-Pro4/luc+ were cultured in
DMEM/10%FCS with 800 and 500 mg/ml geneticine respective-
ly [18]. Huh-7 hepatoma cells were obtained from Cell Bank,
Japan: JCRB0403) and cultured in DMEM/10% FCS. Cells were
counted using an automated cell counter (CASY-TT, Innovatis).
Intracardiac injection of cancer cells
For intracardiac injection of cancer cells, mice were anesthe-
tized (Ketamine 120 mg/kg/xylazine 16 mg/kg). A cancer cell
suspension (105/100 ml PBS) (MDA-MB-231 selected to home to
the bone marrow and establish bone metastases), PC3 or Huh-7
was injected into the left heart ventricle [18]. Tumor growth was
evaluated weekly starting 3 weeks after intracardiac injection by
bioluminescence reporter imaging.
Induction of blood clot
Intratibial bone marrow flushing was performed as described
[18], but without injecting cancer cells intratibially. Briefly, mice
were anesthetized [18,19], skin and muscle were cut and pushed
aside from over the left tibia, two holes, 3–4 mm apart with a
diameter of ,0.35 mm each, were drilled with a dental drill
(Bredent) through bone cortex. Bone marrow was flushed out with
0.5 ml phosphate buffered saline injected in the upper hole, which
was then sealed with surgical bone wax (Ethicon; Johnson and
Johnson) together with the lower hole. Lastly, the cutaneous
wound was sutured. In the homing experiment, the opposite side
was not operated upon to maximize the difference, but in the
growth experiment the control group underwent sham operations
without drilling or flushing.
Bioluminescence imaging
For bioluminescent reporter imaging that allows following bone
metastasis growth longitudinally, mice were anesthetized with
isofluran and injected with d-luciferin (150 mg/kg body weight)(-
Synchem). Exactly 5 minutes after injection, photon signal was
detected using an ‘‘IVIS-100’’ imaging system, and evaluated
using the analysis software ‘‘Living Image’’ (version 2.50).
X-ray analysis
Lytic lesions were detected by radiography using a Faxitron.
Lytic lesions on x-rays were analyzed using ‘‘Image J’’ (Wayne
Rasband, NIH).
Staining protocols, histomorphometry and
determination of clot area
Bones were fixed in 3.7% neutral-buffered formalin (NBF),
embedded in polymethylmethacrylate, sectioned and stained per
Masson Goldner with hematoxilin (Gill II, Carl Roth, Karlsruhe,
Germany), acid fuchsin-ponceau xylidine, and phosphomolybdic
acid-orange G and light green [20]. For dynamic histomorphom-
etry, calcein was administered twice, once immediately after clot
induction and then 48 hours later intraperitoneally at 30 mg/kg
(Sigma-Aldrich, Munich, Germany), and mice euthanized
24 hours later. Primary cancellous bone was defined as the
120 mm band below the growth plate. Cancellous bone was
defined as the remaining trabecular area that extends down 2 mm
[21]. The same sections were used for dynamic and static
histomorphometry, and data obtained from evaluation of the
cancellous bone area defined above are presented. The ASBMR
nomenclature was used [22]. The following measurements are
mentioned: osteoid surface (OS), bone surface (BS), osteoblast
number (Ob.N), bone formation rate (BFR=MS*MAR/BS,
mm2/mm/yr.), number of osteoclasts (Oc.N), and erosion surface
(ES). ImageJ was used (Wayne Rasband, NIH). Staining for
thrombin was performed on plastic sections using a polyclonal
antibody directed against thrombin (Abcam 92621) for one hour.
The secondary antibody used was a goat anti-rabbit antibody
labeled with Alexa 647 (Abcam 150079). Blood clot size was
determined after initial screening of the sections to determine the
section with the largest clot size. The selected sections were stained
per Masson-Goldner. The apparent hematoma area after 5 min,
24 h and 48 h of clot induction was analyzed using ImageJ
(Wayne Rasband, NIH). To perform enzymatic stains 5 mm
cryosections of 3.7% neutral-buffered-formalin-fixed bones were
performed using adhesive film (SECTION-LAB Co. Ltd.) as
described [23]. Until further use the sections were stored at
280uC. TRAcP (tartrate-resistant acid phosphatase) to detect
osteoclasts was stained as described [24]. Briefly: the slides were
placed in dH2O and the following solution was prepared: 16 mg
Naphthol ASTR phosphate (Sigma) was dissolved in 1 ml
dimethylformamide. The Naphthol ASTR phosphate was added
to 10 ml 0.1 M acetate buffer with Pararosaniline and the pH
adjusted to 5.0. Finally 3 drops of Manganese sulfate were added.
Blood Clot Effects on Cancer Cell Homing and Tumor Growth
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The wet slides were incubated 4 mins with the staining solution
and after gently rinsed with dH2O and mounted with Mowiol.
Alkaline phosphatase staining to detect osteoblasts was performed
as described [25]. Briefly, slides were placed in Tris buffer. And
the following staining solution prepared: 40 mg Naphthol ASBI
phosphate (Sigma) was dissolved in 2 mL of dimethylformamide
(Merck). 40 mg of Fast Blue RR salt (Sigma) was dissolved in 2 mL
of dimethylformamide. To prepare the final staining solution,
2 mL of naphthol ASBI solution was combined with 2 mL of Fast
Blue RR salt solution. This was then added to 35 mL of Tris
buffer (pH 9.4, Roth). The solution was filtered before use and was
prepared fresh as the substrate deteriorates over time. The slides
were incubated for 2 min in the staining solution. After incubation
in stain, slides were rinsed in dH2O and mounted with Mowiol.
Alkaline phosphatase–rich structures are stained a dark blue color.
The number of TRAcP osteoclasts was counted and the surface of
alkaline phosphatase stain was measured and adjusted to total
bone surface as described [26]. Sections were photographed using
a Keyence microscope and processed using ImageJ. Quantifica-
tion was performed in at least three mice per group or more as
noted in the figure legends.
DNA analysis
For evaluating the homing of circulating tumor cells mice were
sacrificed 1 h, 4 h, 24 h and 48 h after intracardiac injection and
bones and bone marrow taken for further analysis.
Genomic DNA was isolated from bone marrow using DNeasy
Blood and Tissue kit (Qiagen). Quantitative real-time polymerase
chain reaction (qPCR) was performed using a light cycler 2.0
Instrument (Roche) using the following primers and probes that
detect resistance towards Geneticin in the construct introduced in
the MDA and PC3 cell lines to allow bioluminescence imaging in
a method similar to the use of the alu sequence described by other
groups [27]. These primers however overcome the problem with
contamination by human DNA and are as follows: forward 59-39:
ACTGTTCGCCAGGCTCAAGGC, reverse 59-39 GCGAA-
TCGGGAGCGGCGAT and probe #31. Huh-7 cells were
detected using the following primers and probe: forward: 59CAT
GGT GAA ACC CCG TCT CTA 39; reverse: 59GCC TCA
GCC TCC CGA GTA G 39; probe: 59 ATT AGC CGG GCG
TGG TGG CG 39. Results were normalized to mouse bone
marrow cells using probe #64 and primers for b-actin (Universal
probe library, Roche). An external standard curve using known
numbers of human and mouse specific cells was created for
Geneticin (for MDA and PC3), alu (for Huh-7) and b-actin (for
murine bone marrow). Performing qPCR on bone and bone
marrow DNA and comparing the results with a standard curve for
tumor cells in mouse marrow we were able to detect as few as 0.2–
0.5 human cancer cells/106 murine bone marrow cells.
Flow cytometry
Bone marrow was flushed from the upper third of the tibiae
with 100 ml PBS/tibia, red cells lysed, and cancer cells stained with
an APC-conjugated antibody directed against human CD49e,
which is the integrin a5 subunit. This antibody does not bind to
murine cells and detects 96% of MDA cancer cells (Clone NKI-
SAM-1, Biolegend). The antibody was used at a final concentra-
tion of 0.25 mg/ml. Flow cytometry was performed using LSR-2
(BD-Biosciences), and at least 3 million cells were counted per
sample.
Statistical analyses
Analyses were performed using SPSS (V14.0). Comparisons
between two groups were performed using Student’s t-test or
Wilcoxon paired test as appropriate. In the analysis for homing of
cancer cells after different time periods from clot induction a one
way ANOVA was first performed. Analysis of occurrence of tibial
lesions was performed using Fisher’s exact test. Calculations for
sample size ahead of experiments to detect a difference with a
power of 0.80 as well as post-hoc power analysis were performed
using the PS program available online (http://biostat.mc.
vanderbilt.edu/wiki/Main/PowerSampleSize). A test was defined
as significant if p,0.05. Results are presented as mean6standard-
error-of-the-mean (M6SEM).
Results
Intratibial hematoma and clot formation
In order to determine whether the model we contemplated
using indeed resulted in the development of a blood clot within the
bone marrow, we performed the procedure of intratibial bone
marrow flushing in mice and examined the tibiae 5 and 60
minutes, as well as 24, 48 and 72 hours after the end of the
procedure. Sections within the tibia showed the formation of a clot
already within 5 minutes after end of the procedure as seen with
Masson Goldner staining (figure 1 A and inset below). Smaller
clots were still detectable after 24 hours (figure 1B and inset), but
by 72 hours the clot had almost completely resolved (figure 1C).
The presence of the clot was further confirmed by thrombin
staining (figure 1D). Quantification confirmed the decrease in size
of the clot over time (figure 1E).
Effect of blood clot induction on bone
histomorphometry
Cancer growth increases whenever there is an increase in bone
turnover [28]. In order to determine whether flushing of the bone
marrow and the development of a blood clot resulted in increased
turnover we compared the flushed tibia with the opposite side
tibia. The time point used was three days after the procedure to
allow for cell changes to take place. As shown in figure 2, no
obvious differences could be detected in bone sections. Both
dynamic and static histomorphometric analyses were performed.
Despite a trend to increased osteoblast numbers (p = 0.09), bone
formation rate remained similar. Bone resorption was not affected
as evidenced by similar osteoclast numbers and erosion surface on
static histomorphometry. Using enzymatic staining we confirmed
the absence of an effect on both osteoblasts (by measuring the
surface of alkaline phosphatase staining) (figure 3A) and on
osteoclasts (by counting the number of tartrate-resistant acid
phosphatase-stained osteoclasts) (figure 3B).
Thus, induction of a blood clot does not affect bone turnover by
the time the clot resolved.
Intratibial hematoma formation is not associated with
increased homing of cancer cells
We then sought to examine whether the presence of a blood clot
was associated with increased number of cancer cells arriving to
the clot. We used three different cell lines, one that was selected to
home to the bone marrow and form breast cancer metastases
(MDA-MB-231B/luc+), one that forms prostate metastases in the
bone (PC3/luc+) and a hepatoma cell line not reported to form
bone metastases. Since these are human cell lines, they have to be
used in immune-deficient mice lacking mature T-cells to avoid
destruction of the human cells. Mice underwent intracardial
injection of cancer cells followed one minute later by flushing of
bone marrow in the left tibia. Twenty-four hours later the upper
half of the left tibia (site of intratibial clot induction) was isolated
and the number of tumor cells arriving at the site was evaluated
Blood Clot Effects on Cancer Cell Homing and Tumor Growth
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e94922
using quantitative real time polymerase chain reaction (qPCR) to
determine the number of cancer cells, whereby the frequency of a
specific sequence found exclusively in the cancer cell line corrected
to murine b-actin reflecting the number of murine bone marrow
cells was used. As a control, the right tibia (site without clot
induction) was evaluated. Injecting these cell lines intracardially
one minute before clot induction was not associated with a change
in cancer cells homing to the bone marrow (figure 4A). Using flow
cytometry we were able to confirm the absence of a difference in
the breast cancer cells (MDA-MB-231B/luc+) cells (figure 4B). We
then asked whether the use of surgical wax might have any
inhibitory effect on homing of cancer cells. This was not the case,
because injecting MDA cancer cells 1 minute before clot induction
did not affect the total number of cancer cells at the site of the clot
both in the presence or absence of wax (figure 4C). We next
evaluated whether injecting cancer cells at different time points has
any effect on homing, and injected cancer cells 15 minutes before,
1 minute before and 5 minutes after clot induction. Here too, there
was no difference in the number of cancer cells homing to the
bone marrow (figure 4D). We then wondered, whether homing
was affected by the length of time since injections. Therefore the
number of cancer cells that homed to the clot was evaluated at
Figure 1. Induction of hematoma and clot formation in the bone marrow. (A) Induction of bleeding results in clot formation within 5
minutes as evidenced by Masson-Goldner staining. Bar represents 500 mm. The enlarged inset below shows the blood clot. Bar represents 100 mm. (B)
The clot is still present, albeit partially reorganized at 24 hours after bleeding induction. Bar represents 500 mm. Enlarged inset is shown below. Bar
represents 100 mm. (C) After 72 hours the clot resolved. (D) Thrombin staining of the bone shown in B confirms the presence of thrombin (in red) in
the clot area. (E) Quantification of the change in hematoma size at different time points. After induction of bleeding in the bone marrow, mice were
euthanized at the times mentioned, and tibiae examined. n = 3–4 mice/time point.
doi:10.1371/journal.pone.0094922.g001
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Figure 2. Bone histomorphometry after clot induction. (A–B) After three days from the time of induction of a blood clot Masson-Goldner
staining (on the left) and calcein labeling (on the right) showed no difference between control (CT) in panel A and hematoma induction in panel B in
the same mouse. Neither osteoblast number (C), nor bone formation rate (D), nor osteoclast number (E), nor erosion surface (F) were different
Blood Clot Effects on Cancer Cell Homing and Tumor Growth
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different time points after clot induction followed by injection of
cancer cells. There was no difference in the number of human
cancer cells arriving at the site of intervention compared to the
opposite side after one, four, 24 and 48 hours in a one-way
ANOVA (figure 4E in the 21 min group). A similar experiment
was performed, whereby cancer cells were injected after clot
induction (+5 min group). At 1 hour, less cancer cells were
detected in the hematoma, but this effect was lost at later time
points (figure 4F). This suggests that the presence of a blood clot
does not offer a permissive environment for homing of cancer cells.
Metastasis development in the presence of hematoma
We next examined whether the formation of a blood clot was
associated with an increase in the chance of metastatic lesion
formation. Two experimental mice groups were evaluated. In the
first group (21 min), the mice underwent intracardial cancer cell
injection followed 1 minute later by the procedure to induce
intratibial clot formation. In the second group (+5 min), the mice
underwent the procedure to induce intratibial clot formation,
followed by injection of cancer cells into the left ventricle five
minutes later. Tumor cells injected intracardially circulate for
approximately one hour after which time most cells are cleared
from the circulation. Twenty-four hours later no bioluminescence
signal can be detected (data not shown). The control sham-
operated group received only intracardiac cancer cell injections
without clot induction in the left tibia.
Weekly bioluminescence measurements starting three weeks
after cancer cell injection were performed. This was possible
because the cancer line used contained a luciferase construct [18].
Since the cancer cell line has been selected to only home to the
between the two tibiae. CT represents the right tibia without clot induction and hematoma represents the left tibia in which bone marrow was
flushed and a blood clot was induced. Tibiae were obtained three days after clot induction in the left tibia, embedded in polymethylmethacrylate and
stained using Masson-Goldner. n = 4 mice.
doi:10.1371/journal.pone.0094922.g002
Figure 3. Enzymatic staining of bone sections. (A) Osteoblast surface as evidenced by evaluating the surface stained positive for alkaline
phosphatase did not differ between CT and hematoma bones. A representative stained pair of tibiae is shown on the left and quantification is shown
on the right. (B) The number of osteoclasts as evidenced by counting the cells that stained positive for tartrate-resistant acid phosphatase and
correcting to bone surface was not affected by clot induction. A representative stained pair of tibiae is shown on the left and quantification is shown
on the right. CT represents the right tibia without clot induction and hematoma represents the left tibia in which bone marrow was flushed and a
blood clot was induced. Tibiae were obtained three days after clot induction in the left tibia, fixed in 3,7% PFA, cryo-sectioned using adhesive film
and stained as outlined in the methods. n = 4 mice.
doi:10.1371/journal.pone.0094922.g003
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Figure 4. Infiltration of blood clots by cancer cells. (A) Induction of a blood clot in the left tibia does not result in an increase in the number of
infiltrating cancer cells compared to the right control tibia (CT) in the same mouse when cancer cells are injected 1 minute before blood clot
induction using three cell lines (Breast cancer selected to home to the bone marrow: MDA-MB-231B/luc+; prostate cancer able to form bone
metastases: PC3/luc+; and hepatoma cells not reported to form bone metastases: Huh-7). Cancer cells were injected 1 minute before clot induction.
24 hours later the bone marrow was isolated from the upper third of both tibiae and the number of cancer cells was evaluated by quantitative PCR of
Blood Clot Effects on Cancer Cell Homing and Tumor Growth
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bone marrow, no lesions outside the skeleton could be detected.
Examples from 5 pairs of bioluminescence and x-ray pictures
obtained from CT and the +5 min group are presented in figure 5.
Seven weeks after cancer cell injection 13 out of 18 mice (72%)
of the mice in the control group developed lesions in the left tibia.
Intracardiac cancer cell injection prior to clot induction (21 min)
resulted in 11 affected in the left tibia (out of 14 mice) (79%).
Similarly, injection of cancer cells 5 minutes after clot induction
resulted in 11 mice affected with left tibia lesions (out of 17 mice)
(65%) (figure 6A). Examined differently, a total of 115 lesions had
developed in the control group, out of which 13 (11%) were
localized in the left tibia and 17 in the right tibia. Intracardiac
cancer cell injection prior to intratibial flushing (21 min) resulted
in 85 bone metastatic lesions, out of which 11 (13%) were localized
to the left tibia, and 11 in the right tibia (n = 18 and 14 mice,
p = ns), while injection of cancer cells 5 minutes after clot
induction resulted in 89 bone metastatic lesions, out of which 11
(12%) were localized to the left tibia, and 11 in the right tibia
(n = 18 and 17 mice, p = ns) (figure 6B). The summary of the lesion
numbers and their locations at 7 weeks after cancer cell injection
(including mice that died prior to seven weeks) are presented in
Table 1 (sample size was calculated a priori for a power of 0.80).
This suggests that with a post hoc power of 0.89 (21 min group)
and 0.92 (+5 min group) the presence of a blood clot does not
affect the development of a macroscopic lesion. Tumor burden
was not affected since the total bioluminescence signal per mouse
(figure 6C), and per lesion (figure 6D) did not differ between the
experimental and the control group. In support of these findings,
analysis of x-ray films obtained at seven weeks after cancer cell
injection revealed comparable sizes of lytic lesions between the
groups (figure 6E). In line with these findings, median survival did
not differ between all three groups (CT 7.5 weeks; 21 min group
8.0 weeks; +5min group 8.5 weeks; p = ns for the CT and
experimental pairs) (figure 6F).
Based on these findings, we conclude that the presence of a
blood clot does not affect the development of a macroscopic lesion
or the growth characteristics of bone metastases in a murine model
of breast cancer metastasis.
Discussion
The principal finding of our study is that the formation of a clot
and hematoma in the bone marrow neither increases the chance
that a cancer cell becomes incorporated in the clot, nor is it
associated with an increase in the chance that a metastatic lesion
develops in the area of the clot, nor does it affect the later growth
of tumors.
With experimental evidence emerging in 1990s the seed and soil
theory that implies that homing and growth of cancer cells is
facilitated in locations that provide the right microenvironment,
has gained much ground among scientists working on metastasis
formation [29]. The accumulation of blood outside a blood vessel
results in the activation of the coagulation cascade associated with
the formation of a blood clot, with the ensuing accumulation of
thrombin and various other proteins that support tumor estab-
lishment and growth [9–11]. Clot formation is also associated with
activation of platelet aggregation, which release SDF-1, VEGF
(Vascular endothelial growth factor) and PDGF (platelet-derived
growth factor) [14,30,31]. These three molecules were shown to
exert pro cancerous effects. While SDF-1 normally serves as a
a cancer cell specific sequence and corrected to the total number of murine cells in the sample. n = 4–5/group. (B) The number of MDA cancer cells
evaluated by flow cytometry was similar between the CT and hematoma group. MDA cancer cells were injected 1 minute before clot induction.
24 hours later the bone marrow was isolated from the upper third of both tibiae, red cells lysed, stained with a labeled human-specific CD49e
(integrin a5) antibody and at least 3 million bone marrow cells were counted. n = 10 mice. (C) The use of surgical wax in the tibia following clot
induction does not affect homing of cancer cells. 1 minute before clot induction MDA cancer cells were injected. The hole performed in the tibia in
order to induce the blood clot in the bone marrow was either closed with surgical wax or left until bleeding stopped spontaneously (3–5 minutes)
before closing the wound. n = 4 pairs. (D) Injection of MDA cancer cells 15 minutes before, 1 minute before and 5 minutes after clot induction did not
affect the number of cancer cells in the bone marrow detected after 24 hours. Samples were prepared as in A. p = ns for each time point. (E)
Evaluation of cancer cell numbers when injected 1 minute before clot induction did not reveal a difference in the number of cancer cells detected in
the bone marrow at different time points (1, 4, 24 and 48 hours after clot induction). p = ns and n= 4–5 per time point. (F) Evaluation of cancer cell
numbers when injected 5 minutes after clot induction showed a significant decrease in the number of cancer cells detected in the bone marrow at
1 hour after clot induction (p,0.05) but not at later time points (4, 24 and 48 hours after clot induction) (p = ns). n = 4–8 per time point.
doi:10.1371/journal.pone.0094922.g004
Figure 5. Bioluminescence and x-ray imaging in vivo. Represen-
tative bioluminescence images from the last measurements before
death and x-ray images at the time of death from 5 CT and 5
experimental mice in the group injected with cancer cells 5 minutes
after clot induction. Upper panel represents the paired pictures from
the CT group and the lower panel represents the paired pictures from
the experimental group.
doi:10.1371/journal.pone.0094922.g005
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Figure 6. Comparison of control and experimental groups. (A) In the control group 13 lesions developed in the left tibia while in both
experimental groups 11 developed in the left tibia. The percentages of mice with lesions in the left tibia is shown. n= 18, 14 and 17 mice. (B) The
percentage of left tibia lesions in comparison to the total number of lesions is similar in both CT-experimental group pairs. n as in A. (C) Total
bioluminescence signal per mouse expressed in relative light units (RLU) was similar between the control and the experimental groups at 7 weeks.
n = 12, 11 and 15 mice. (D) Total bioluminescence signal per lesion was similar too. n as in C. (E) The size of the lytic lesions at 7 weeks was
comparable. n as in A. (F) Survival curves of the control group (CT) and the experimental +5 min hematoma group shows that there is no difference in
median survival (7.5 vs. 8.5 weeks, p = ns). n as in A. For ease of presentation CT was compared with the group with the seemingly larger median
survival only.
doi:10.1371/journal.pone.0094922.g006
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chemotaxis signal for platelets and inflammatory cells to initiate
the wound healing process [14,32], it is similarly chemotactic for
cancer cells and was shown to stimulate cancer cell migration and
establishment in the bone marrow [33]. Therefore, in its presence,
cancer cells in the circulation would be expected to proceed to the
site of clot formation. Both PDGF and VEGF support angiogen-
esis [34–36]. However angiogenesis is only required at a later time
point when the lesion is already about 1 mm3 in size [37]
indicating that this effect should influence only tumor growth and
development but not the homing of circulating cancer cells. Lastly,
platelets promote cancer development by impairing the function of
natural killer cells [38]. Thus the accumulation of platelets in a
blood clot should be permissive to cancer cell homing and may
promote growth.
Associated with the flushing of the bone marrow, shear forces
on the blood vessels and the sinusoids result in leakage of blood
with all its components into the bone marrow cavity. Nevertheless
no increase in the number of cancer cells trapped in the clot could
be detected. It thus seems that the prometastatic roles of various
members of the coagulation cascade and the platelets in the
cytokine rich environment of the bone marrow are not critical at
physiologic concentrations for the early development of cancer
lesions or for their later growth. The lack of effect on growth
starting after 3 weeks could however be due to recovery and
resolution of the blood clot by then. Lastly, an inhibitory role due
to the presence of megakaryocytes cannot be excluded, because
megakaryocytes in the bone marrow have been shown to induce
apoptosis and decrease proliferation of prostate cancer cells [39].
Bone marrow disruption is associated with the formation of a
mineralizing trabecular network and an increase in osteoblasts
[40]. Untreated osteoblasts in vitro and osteoblasts lining the bone
marrow in vivo release a variety of cancer promoting cytokines such
as interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-
1) [4,41], both of which have also been shown to promote cancer
cell migration and invasion [4,42,43]. We therefore performed
histomorphometric analyses of the bone after clot induction [41].
However, flushing the bone marrow in our model did not induce
significant changes in bone formation as shown in figures 2 and 3.
This contrasts to histologic changes shown with disruption of the
bone marrow and reported before [40], and is in line with the lack
of a difference in cancer development between the flushed tibia
and the opposite sides. The clot induction was not associated with
an increase in bone resorption either. Therefore, the release of
growth factors from the bone matrix in our model of clot induction
is limited [44]. Thus, our model stands in contrast to fracture
models where the broken bone results in the formation of a blood
clot followed by infiltration by inflammatory cells, formation of the
fibrocartilagenous callus, and finally bone remodeling resulting in
normal bone structure in the area of the fracture. Even though
inflammation is associated with the release of some cytokines that
affect bone cells, and hence a low level of bone remodeling with
release of growth factors from the matrix might ensue during the
early stages after fracture formation [45–47], the major remod-
eling step during fracture healing takes place after the blood clot
had resolved [48]. Our experimental clot induction model
examines the effect of blood clot formation within the cytokine-
rich environment of the bone marrow. Because of the absence of
measurable bone remodeling it thus does not include the role of
the growth factors released from the matrix during remodeling.
However, the bone marrow itself is a microenvironment already
rich with cytokines that can promote cancer cell homing and
growth [49], whereby the same cytokines required for hemato-
poiesis seem to be beneficial for homing of cancer cells to the bone
marrow and tumor growth. One such cytokine is SDF-1 that is
involved in hematopoiesis and chemotaxis [14,50]. Furthermore,
osteoblasts release a variety of cancer promoting cytokines that
support cancer development as discussed [4,42,43]. The similar
homing and cancer growth between the flushed side and the
opposite side in our model therefore suggests that blood clots even
in a cancer-promoting environment do not necessarily support
cancer formation.
Table 1. Comparison of control and experimental groups.




Hematoma group -1 min
n=14 (%)*
Hematoma group +5 min n=17
(%)*
Total number of bone lesions 115 85 89
Left tibia (Control or hematoma) 13 (11) 11 (13) 11 (12)
Right tibia 17 (15) 11 (13) 11 (12)
Cranium and jaw 17 (16) 12 (14) 17 (19)
Spine 16 (14) 12 (14) 14 (16)
Ribs 1 (1) 3 (4) 3 (3)
Shoulder 6 (5) 8 (9) 5 (5)
Hip 6 (5) 7 (8) 2 (2)
Femur 7 (6) 4 (5) 8 (9)
Humerus 15 (13) 5 (6) 8 (9)
Forelimb foot 9 (8) 6 (7) 5 (5)
Hindlimb foot 8 (7) 6 (7) 8 (9)
Number of lesions/mouse 6.4 6.1 5.3
The number of macroscopic lesions detectable by bioluminescence imaging in the left tibia was similar between control animals that did not undergo clot induction
and experimental animals with a blood clot in which cancer cells were injected 1 minute prior to (21 min), or 5 minutes after clot induction (+5 min). Data from all mice
(including those that already died) 7 weeks after cancer cell injection are shown. Data were analyzed using Fisher’s exact test and no significant differences were
detected in the CT/experimental group pairs.
*The percentage presented is calculated as follows: number of lesions at a specific site/total number of lesions in the group.
doi:10.1371/journal.pone.0094922.t001
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The decision to introduce cancer cells by intracardiac injection
was based on the need to provide for a large number of circulating
cancer cells looking for a home during clot induction [51]. This
model thus seems better suited to examine the role of clot proteins
in supporting cancer cell homing and growth than introducing a
cancer, from which the cells would first need to move out and
roam in the blood stream before migrating into the clot [27]. By
using two different time points for the injection of cancer cells in
relationship to induction of blood clotting we evaluated both the
role of the initial thrombin surge and acute release of clotting
factors on already circulating cancer cells (in the 21 min model)
and the role of the presence of a clot prior to the surge in
circulating cancer cells (in the +5 min model). In the case of
introduction of the cancer cells 5 minutes after clot induction (+
5 min) the decrease in the number of cancer cells that homed to
the bone marrow one hour after clot induction was surprising. In
particular since we had expected an increase in homing of cancer
cells to the clot driven by the availability of the various clotting
factors. This decrease could be explained by the volume taken up
by the blood clot that results in a decrease in the volume of
circulating blood in the bone marrow and hence a decrease in the
number of cancer cells [51]. A related possible explanation is that
the blood clot does not allow infiltration by cancer cells due to the
accumulation of matrix. This early effect however does not bear
any relevance to the number of cancer cells at the site of clot after
24 hours or affect the development of cancerous lesions. While our
data do not allow for a conclusion with regard to whether a larger
clot might have caused an increase in the homing of cancer cells, it
seems reasonable to conclude, based on our findings, that the
formation of a 0.5 mm2 clot (as shown in figure 1E) is not
associated with increased homing of cancer cells to the clot after
24 hours.
Even though this experimental model compares favorably to
other cancer models because it is based on a human cancer cell
line and shares the ability to induce bone metastatic lesions with
the clinical human counterpart, other cancer types might be more
responsive to various cancer-promoting effects of physiologic
concentrations of blood clot components. Nevertheless, it seems
safe to predict that the effect in other models is probably limited in
particular since two further cell lines failed to show an increase in
homing of cancer cells to the blood clot.
Conclusions
Based on our findings we therefore conclude that, in a mouse
model of human breast cancer, induction of a hematoma/clot did
not promote bone metastasis formation or growth. Accordingly,
there is currently no experimental evidence to support the
possibility of metastasis formation in freshly injured areas in
patients with cancer. It seems more likely that the coincidence of
metastasis at sites of surgical interventions or trauma is due
exclusively to chance.
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